GSTM1 and Alpha-thalassemia: Because screening platforms vary in their resolution and sensitivity for detection and quantification of aberrant hemoglobin species, using a different platform for the first round of screening compared with the second round maximizes the number of persons identified with Hb Bart’s levels indicative of alpha-thalassemia.